Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
ASCO: new Sarclisa data support subcutaneous administration with on-body injector
Paris, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa's efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.
Alyssa Johnsen, MD, PhD
Global Therapeutic Area Head, Immunology and Oncology Development
'Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation thatcouldimprove and streamline the treatment process for both patients and providers. We are pleased to share thesedata, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forwardtopotentiallybringing this formulation and administrationoptionto the multiple myeloma community.'
The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.
The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections' enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa. The enFuse device uses a 30 gauge, hidden, and retractable needle that is smaller compared to some of the commonly used large-volume SC injection needles, which may support patient comfort.
The safety and efficacy of Sarclisa SC administered with the OBI or manual administration are investigational and have not been approved for use by any regulatory authority.
IRAKLIA phase 3 study
IRAKLIA is a global, randomized, open-label, pivotal phase 3 non-inferiority study comparing Sarclisa SC administered via an OBI and Sarclisa IV, both in combination with pomalidomide and dexamethasone (Pd) in adult patients with R/R MM who have received at least one prior line of treatment. At the data cut-off of November 6, 2024, and a median follow-up of 12 months, the study demonstrated:
Primary endpoints
Secondary endpoints
The overall safety profile of Sarclisa SC-Pd observed in this study was consistent with the established safety profile of Sarclisa IV-Pd, but with a notably lower rate of systemic IRs. No new safety concerns were observed, except for low-grade local injection site reactions (ISRs) associated with SC administration that occurred with a low incidence (0.4%, n=19/5,145 injections). Nearly all ISRs were grade 1, except for one episode of grade 2.
Xavier Leleu, MD, PhD
Head of the Department of Hematology and Myeloma Clinic at the Hôpital La Mileterie and study investigator
'Results from the IRAKLIA phase 3 study represent a potentially transformational advancement in the administration of multiple myeloma treatment. These data not only establish non-inferiority between Sarclisa administered both subcutaneously and intravenously across several key endpoints but reinforce the positive impact that this on-body injector could have on the patient treatment experience, as demonstrated by patient satisfaction scores.'
In addition to the oral presentation at ASCO, the full data were simultaneously published in the Journal of Clinical Oncology.
IZALCO phase 2 study
In addition to the IRAKLIA phase 3 study, Sanofi also presented new data from the randomized, sequential, open-label, IZALCO phase 2 study evaluating the efficacy and safety of Sarclisa SC administered via manual push or an OBI, in combination with carfilzomib and dexamethasone (Kd) in adult patients with R/R MM who have received one to three prior lines of therapy. At a median follow-up of 10.1 months, the study demonstrated:
The overall safety profile of Sarclisa SC-Kd observed in this study was consistent with the established safety profile of Sarclisa IV-Kd, with no new safety concerns observed.
Advancing patient and provider-centric innovation in MM
While SC administration is currently available for certain MM treatment regimens through a manual injection, administering large-volume medicines manually can present significant challenges, including a labor-intensive process for nurses, risk of strain and needlestick injuries, and potential need for larger needles that may compromise patient comfort and increase anxiety.
Mehul Desai, PharmD, MBA
Vice President, Medical Affairs, Enable Injections
'We believe multiple myeloma patients deserve a more convenient and comfortable treatment experience and recognize the crucial role providers play in delivering that care. Through our collaboration with Sanofi, we've aspired to advance an on-body injector that could transform the treatment experience for patients and providers alike. The results from the IRAKLIA and IZALCO studies represent a significant step toward our ambition and validate the potential of the on-body injector to deliver the same high standard of efficacy established with intravenous Sarclisa.'
In addition to IRAKLIA and IZALCO, Sanofi is also evaluating Sarclisa SC administration via an OBI in the front-line treatment setting. The ISASOCUT phase 2 study conducted by the University of Poitiers, is evaluating Sarclisa in combination with bortezomib, lenalidomide and dexamethasone (VRd) in adult patients with newly diagnosed MM (NDMM) not eligible for autologous stem-cell transplant (ASCT), while the German-speaking Myeloma Multicenter Group (GMMG)-HD8 phase 3 study, conducted in collaboration with the GMMG and the German Multiple Myeloma Study Group Consortium (DSMM), is evaluating Sarclisa SC-VRd induction in NDMM patients who are eligible for ASCT. In addition, results from the IZALCO, IRAKLIA and ISASOCUT studies will be presented at the European Hematology Association Congress later this month. The IRAKLIA abstract was also hand-selected to be included in the 2025 Best of ASCO program, held later in the summer of 2025, following the ASCO Annual Meeting. The data from these studies, collectively, will form the basis for global regulatory submissions.
Sarclisa administered subcutaneously via the on-body injector or manual administration is investigational and has not been approved for any use by any regulatory authority. The safety and efficacy of this formulation and delivery method have not been established.
About the IRAKLIA and IZALCO studies
IRAKLIA is a randomized, open-label, pivotal phase 3 study evaluating the non-inferiority of Sarclisa SC formulation administered at a fixed dose SC via an OBI versus weight-based dosed Sarclisa IV in combination with Pd in adult patients with R/R MM who have received at least one prior line of therapy. The co-primary outcomes being assessed are ORR, defined as the proportion of patients with stringent CR, CR, VGPR, and partial response (PR) according to the 2016 IMWG criteria assessed by Independent Review Committee (IRC), and observed C trough at steady state (pre-dose at C6D1), defined as observed Sarclisa plasma concentrations.
IZALCO is a two-part, randomized, sequential, open-label, phase 2 study evaluating the efficacy and safety of Sarclisa SC formulation administered SC via manual push or an OBI in adult patients with R/R MM who have received one to three prior lines of therapy. The primary objective is ORR, as assessed by IRC. The secondary objective is patient preference for the OBI versus manual administration of Sarclisa SC.
About Enable Injections
Based in the US (Cincinnati, OH), Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of enFuse. enFuse is an innovative wearable drug delivery platform that is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. For more information, visit https://enableinjections.com.
About Sarclisa
Sarclisa (isatuximab) is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple treatment lines for MM. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in the US, EU and Japan in combination with Pd for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor and have relapsed on the last therapy; this combination is also approved in China for patients who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, UK, and China, Sarclisa is approved in combination with VRd as a front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study. In Japan, Sarclisa is approved in combination with VRd as a front-line treatment option regardless of transplant eligibility.
At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need.
For more information on Sarclisa clinical studies, please visit www.clinicaltrials.gov.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | [email protected]
Evan Berland | +1 215 432 0234 | [email protected]
Léo Le Bourhis | +33 6 75 06 43 81 | [email protected]
Victor Rouault | +33 6 70 93 71 40 | [email protected]
Timothy Gilbert | +1 516 521 2929 | [email protected]
Investor Relations
Thomas Kudsk Larsen |+44 7545 513 693 | [email protected]
Alizé Kaisserian | +33 6 47 04 12 11 | [email protected]
Felix Lauscher | +1 908 612 7239 | [email protected]
Keita Browne | +1 781 249 1766 | [email protected]
Nathalie Pham | +33 7 85 93 30 17 | [email protected]
Tarik Elgoutni | +1 617 710 3587 | [email protected]
Thibaud Châtelet | +33 6 80 80 89 90 | [email protected]
Yun Li | +33 6 84 00 90 72 | [email protected]
Sanofi forward-looking statements All trademarks mentioned in this press release are the property of the Sanofi group with the exception of enFuse.
Attachment
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
27 minutes ago
- Medscape
Could Kids' Gut Bacteria Trigger Young Colorectal Cancer?
According to a study published in Nature by an international team led by the University of California, San Diego, childhood exposure to the bacterial toxin colibactin could drive early-onset colorectal cancer (CRC). The first author is Marcos Díaz-Gay, PhD, head of the new Digital Genomics Group at the Spanish National Cancer Research Center (CNIO) in Madrid, Spain. CRC is considered a disease associated with aging; however, its incidence in adults younger than 50 years has approximately doubled each decade over the past 20 years in various countries. If current trends persist, it could become the leading cause of cancer-related deaths among young adults by 2030. Childhood Exposure Díaz-Gay told the Medscape Spanish edition that it remains unclear what factors over the past two decades have driven the rise in CRC among younger adults. 'Our study is one of the first to address this question, and it offers a partial answer. It supports the hypothesis that colibactin exposure contributes to this increase; however, the finding is correlative rather than causal. We need further evidence to prove causality,' said Díaz-Gay. He noted that although diet and lifestyle have changed over the past 20 years, 'but the changes occurred earlier, since these people are currently between 20 and 50 years old. With respect to colibactin, we are talking about exposures in the first 10 years of life,' he added. He emphasised that the study does not claim that colibactin is the cause of all cases in young patients, nor does it exclude its role in older adults. 'It is true that we see it more frequently in people under 50, but we also observe it in older people; in fact, 10% of those over 50 also have these mutations,' said Díaz-Gay. Mutational Patterns Colibactin is a toxin produced by certain Escherichia coli strains that damages the cellular DNA. The study showed that exposure to this toxin during early childhood imprints a characteristic genetic signature on the DNA of colon epithelial cells. 'The mutational pattern that colibactin imprints on the genome was already known,' Díaz-Gay explained. In 2020, Hans Clevers and Spanish collaborators conducted a study using organoids, in which a specific mutational profile induced by the toxin was observed. Michael R. Stratton's group subsequently identified the same profile in normal colon cells, noting its emergence and enrichment during childhood, when tumours are at their earliest developmental stages and are clearly enriched at that time. 'We confirmed that they are also present in early tumour stages,' said Díaz-Gay. The novel finding of this study was that the mutational patterns associated with colibactin were more frequent in patients younger than 50 years. 'We identified this internationally in nearly 1000 sequenced patients,' he said. Mutation Burden The investigators analysed 981 CRC genomes from 11 countries. The results showed that colibactin leaves specific DNA mutation patterns, which are true mutational signatures. These signatures are 3.3 times more frequent in adults diagnosed before the age of 40 years than in those diagnosed after the age of 70 years. Moreover, the overall colibactin signatures are especially prevalent in countries with high rates of early-onset CRC. The study found no significant differences in cancers with microsatellite instability but observed variations in the mutation burden and signatures in 802 microsatellite-stable cases. Multiple signatures, most of which have unknown aetiology, showed variable prevalence in Argentina, Brazil, Colombia, Russia, and Thailand, indicating geographically diverse levels of mutagenic exposure. The SBS88 and ID18 signatures, caused by the mutagen colibactin, showed higher mutation loads in countries with higher CRC incidence. SBS88 and ID18 were also enriched in early-onset CRC, being 3.3 times more common in those diagnosed before the age of 40 years and appearing in the earliest stages of tumour development. Colibactin exposure is linked to driver mutations in the tumour suppressor gene APC ; the mutational signature ID18 accounts for approximately 25% of APC insertions or deletions in colibactin-positive tumours. Conceptual Shift 'These mutation patterns are a kind of historical record in the genome,' said Ludmil Alexandrov, PhD, professor in the Shu Chien-Gene Lay Department of Bioengineering and the Department of Cellular and Molecular Medicine at University of California, San Diego, who is also a member of University of California, San Diego Moores Cancer Center and deputy director of Sanford Stem Cell Fitness and Space Medicine Center, San Diego, and lead author of the study, in a CNIO press release. 'If someone acquires one of these driver mutations at age 10,' Alexandrov explained, 'they could be decades ahead of the curve in developing colorectal cancer and develop it at age 40 instead of 60.' Alexandrov also pointed out the conceptual shift these results represent; many cancers can be traced to environmental or microbial exposures in the first years of life, long before diagnosis. 'This changes the way we think about cancer. It is not just about what happens in adulthood but also in the first decade of life, even in the first few years.' 'Until now, we had no satisfactory explanation for the increased incidence of CRC in young patients.' Various hypotheses have been proposed, but without conclusive data. 'The newly published study offers a solid and interesting hypothesis to explain this phenomenon and suggests a potential preventive strategy,' Andrés Muñoz, MD, a medical oncologist at Gregorio Marañón University Hospital in Madrid, Spain, told Medscape Spanish edition. On whether it would be appropriate to implement screening protocols to detect these cases in young people, Muñoz said: 'Before any screening or therapeutic protocol is introduced, these highly relevant findings must be validated and replicated in other studies and patient cohorts.' He added that genetic analyses to detect these mutations are currently only available at the research level, making their clinical application difficult. Díaz-Gay explained: 'We perform whole genome sequencing of tumour biopsies and blood cells as normal tissue to identify tumour mutations, but this is not applicable in clinical practice, where specific genes relevant to a given tumour are analysed.' He noted a desire to detect these mutations non-invasively via liquid biopsy or stool analysis rather than genetic testing but said that the effort is at an early stage. Geographic Variation The study found that SBS88 and ID18 were prevalent in cancers from specific countries — namely Argentina, Brazil, Colombia, Russia, and Thailand — suggesting that local environmental exposure may contribute to cancer, although the factors remain unknown. Spain was not included in this part of the study design, which focused on molecular differences among those countries, 'but ultimately the primary objective became recognising differences between age groups,' Díaz-Gay said. Although country-specific differences were found, the overall similarities in these tumours were considerable: 'There are specific genetic signatures, though not for colibactin, but in the mutational processes driving tumours. We have seen very concrete signatures in Argentina and Colombia; in these cases, though we could not determine the source, they could be related to microbial environmental exposures or other toxins.' On other little-known environmental carcinogens, Díaz-Gay said that none stand out for the colon at present but that mutation pattern analysis has yielded major discoveries in recent years: 'New environmental factors causing kidney cancer mutations have been identified — for example, aristolochic acid, a highly mutagenic carcinogen linked to traditional medicine plants in countries such as Taiwan,' he explained. He added that some high-risk cancer compounds are not associated with mutations, 'which is notable and the subject of much current research.' Future Research The authors outlined the key questions they would like to address in later phases of this research: How are children exposed to colibactin-producing bacteria, and how can that exposure be prevented? Do specific diets and lifestyles promote colibactin production? How can carriers of these mutations be identified? Trials are underway to assess whether probiotics can eliminate harmful strains and develop stool-based tests for the early detection of colibactin-associated mutations. Díaz-Gay has filed a European patent application with application number EP25305077.7. Conflicts of interest for the other authors are detailed in the original publication. Muñoz has declared having no relevant financial conflicts of interest.
Bloomberg
27 minutes ago
- Bloomberg
Stock Movers: Wizz Air, Wise, Bayer (podcast)
On this episode of Stock Movers: - Wizz Air plunged 26% in early trading after the discount airline reported earnings that missed estimates and refrained from providing a guidance, citing poor visibility. - Wise is planning to list its shares in the US, the latest blow to London's stock market. - Bayer shares rise as much as 5.1% after Goldman Sachs upgrades the German chemicals and pharmaceutical company to buy from neutral, saying it sees earnings as having bottomed out and thinks risks around litigation and pharma data are overdone.
Forbes
38 minutes ago
- Forbes
FC Barcelona Has Door Opened To Julian Alvarez Signing
The agent of Atletico Madrid striker Julian Alvarez, Fernando Hidalgo, opened the door to FC Barcelona pursuing the Argentine with comments he made this week. The former Manchester City marksman has scored against Barca a number of times already in his thus far short career, and is being talked up as a potential long-term heir of Robert Lewandowksi's number 9 shirt in Blaugrana in 2026. That's the year the Pole's contract expires on June 30, and given he'll be approaching his 38th birthday by then, 'Lewa' is likely to move on and continue his career in another country such as the United States. 'The day to day is at Atletico. We will see how the negotiation is. Football is very changeable. They will have to communicate with the club, which will evaluate the situation, and there will be a negotiation between the three parties,' Hidalgo first explained. Hidalgo explained that many clubs have shown interest in his client, but that playing for Barca is a dream for Alvarez because of his idol being Qatar 2022 teammate Lionel Messi. 'He received many calls, but Atletico's position is that Julian continues next season. He has admiration for Spanish clubs and, having followed Leo's career since he was a child, I don't think there are many Argentines who don't have a feeling for Barca, especially with how the team played this season,' Hidalgo teased. Furthermore, Alvarez is 'very grateful' to many Culers and those connected to the club that 'have always spoken very well of him', with Pau Cubarsi mentioned specifically. 'That makes him motivated,' Hidalgo concluded, with Alvarez at present set to face the defender on opposite sides of the ball in La Liga for at least another year before they possibly become teammates. Notorious for getting as much money as possible from FC Barcelona when it can, Atletico Madrid won't make signing Alvarez easy. The club from the capital paid €75 million plus €15 million in variables for him from City not even 10 months ago, and the 25-year-old's value has only increased off the back of a more-than-impressive maiden term in Spain.
